Citations

Clear

585 citation(s) found for "Tran, Ha".

Scanning the Horizon of Sociogenomics: an Assessment of the Development and Growth of Polygenic Indices for Social and Behavioral Traits
Canter, Courtney , Meagher, Karen M. , Cadigan, R. Jean , Koopmann, Amy , Watson, Sara , Kucmanic, Matthew , Ban, Seung Woo, Tran, Thanh N. , Hromcenco, Maria, Foley, Kathleen , Lamb, Jeremy J., Prince, Anya E. R. , Koopmann, Amy M , Callier, Shawneequa , Lamb, Jeremy J , Prince, Anya E R , Meagher, Karen M , Callier, Shawneequa

Mayo Clinic

AJOB Empirical Bioethics | October 30, 2025 | Volume: 17 | Issue: 1 | Pages: 9-19

10.1080/23294515.2025.2576839 | PMID 41165619 Get It

Lichen planus‐like drug eruption: A disproportionality analysis using FAERS database
Tran, Tung S, Le, Duc V. , Nguyen, Trang M , Lehman, Julia S. , Wetter, David A., Nguyen, Giang Huong , Tran, Tung S. , Tran, Tung S , Nguyen, Giang H , Le, Duc V. , Lehman, Julia S , Nguyen, Trang M , Doanh, Le Huu , Wetter, David A.

Mayo Clinic

Journal of the European Academy of Dermatology and Venereology | October 30, 2025 | Volume: 40 | Issue: 5 | Pages: No page available

10.1111/jdv.70140 | PMID 41165063 Get It

Impaired Perfusion and Early Ischemic Stroke Recurrence in Symptomatic Intracranial Atherosclerosis: BIORISK ICAS Study
Yaghi, Shadi , Khan, Farhan , Lewis, Skylar, Stipanovich, Ava, Choi, Richard , Baker, Richard, Kasab, Sami Al , Qdais, Ahmad Abu, Yaddanapudi, Sridhara , Sultana, Sabiha , Khan, Muhib , Malik, Maarij , Klaas, James P. , Bakradze, Ekaterina , Ressler, Hadley W. , McCullough‐Hicks, Margy , Cooper, Dawson C , Pillai, Abhiram Parameswaran, Hariharan, Praveen , Alam, Shaista , Mayer, Morgan, Kugler, Irina, Almiri, William , Secchi, Thaís , Mantovani, Gabriel Paulo , Rothstein, Aaron , Krishnaiah, Balaji , Alfred, Linda Sherine , Vishnu, Venugopalan Y. , Chandu, Meena, Agarwal, Ayush , Marrone, Nicola , Vozzi, Stefano, Ghannam, Malik , Elshikh, Mohamed , Hou, Yan , Peshwe, Krithika Umesh, Tunguturi, Ajay, Frontera, Jennifer , Zaidat, Osama O. , Barakat, Benan , Khan, Niha, Sen, Shayak, Coelho, Mariana Lima , Sousa, João André , Sousa, Diana Aguiar de , Soares, Mafalda , Rodrigues, Amanda Cyntia Lima Fonseca , Jhaveri, Aditya , Bhati, S., Vassilopoulou, Sofia , Tountopoulou, Argyro , Muddasani, Varsha , Henninger, Nils , Tran, Hieu , Helenius, Johanna, Khasawneh, Mohammad W , Vellimana, Ananth K. , Apfel, Ryan , Molaie, Amir , Mannino, Marina , Terruso, Valeria, Halabi, Tarek El , Reda, Mahasen , Tamer, Christel, Shu, Liqi , Khatri, Pooja , Furie, Karen L. , Liebeskind, David S. , Al Kasab, Sami , Klaas, James P , Aemaz Ur Rehman, Muhammad , Leon Guerrero, Christopher R , Ressler, Hadley Walsh , Saleh Velez, Faddi , Owens, Cameron , McCullough-Hicks, Margy , Cooper, Dawson , Parameswaran Pillai, Abhiram , Hariharan, Praveen , Heldner, Mirjam R , Antonenko, Kateryna , Almiri, William , Martins, Sheila , Mantovani, Gabriel , Rothstein, Aaron , Sloane, Kelly L , Krishnaiah, Balaji , Elangovan, Cheran , Vishnu, Venugopalan Y , Chandu, Meena , Agarwal, Ayush , Romoli, Michele , Ghannam, Malik , Elshikh, Mohamed , Dibas, Mahmoud , Hou, Yan , Tunguturi, Ajay , Marto, João Pedro , Duarte Armindo, Rui , Frontera, Jennifer , Kuohn, Lindsey , Almajali, Mohammad , Zaidat, Osama O , Barakat, Benan , Simpkins, Alexis N , Coelho, Mariana , Sargento-Freitas, Joao , Sousa, Joao Andre , Aguiar de Sousa, Diana , Soares, Mafalda , Cyntia Lima Fonseca Rodrigues, Amanda , Jhaveri, Aditya , Morsi, Rami Z , Siegler, James E , Aziz, Yasmin , Harker, Pablo , Vassilopoulou, Sofia , Tountopoulou, Argyro , de Havenon, Adam H , Henninger, Nils , Tran, Hieu , Khasawneh, Mohammad , Vellimana, Ananth , Apfel, Ryan , Molaie, Amir , Mannino, Marina , Terruso, Valeria , Klein, Piers , Shu, Liqi , Khatri, Pooja , Furie, Karen L , Nguyen, Thanh N , Liebeskind, David S. , Prabhakaran, Shyam , Yaghi, Shadi , Choi, Richard , Khan, Farhan , Sultana, Sabiha, Rehman, Muhammad Aemaz Ur , Velez, Faddi G. Saleh , Pinto, Camila Bonin , Alam, Shaista, Mayer, Morgan, Heldner, Mirjam R. , Kugler, Irina, Elangovan, Cheran , Dibas, Mahmoud , Marto, João Pedro , Kuohn, Lindsey , Almajali, Mohammad , Khan, Niha, Simpkins, Alexis N. , Sen, Shayak, Morsi, Rami Z. , Siegler, James E. , Aziz, Yasmin , Harker, Pablo , Bhati, Sonia, Havenon, Adam de , Tamer, Christel, Klein, Piers , Nguyen, Thanh N. , Prabhakaran, Shyam

Mayo Clinic

Stroke | October 23, 2025 | Volume: 57 | Issue: 1 | Pages: 96-106

10.1161/strokeaha.125.053160 | PMID 41128719 Get It

BACKGROUND: Intracranial atherosclerosis (ICAS) is associated with an increased risk of early recurrent ischemic stroke. We evaluated whether biomarkers of impaired distal perfusion—specifically, anterior circulation borderzone infarct, and hypoperfusion mismatch volume—were associated with recurrent ischemic stroke within 90 days. METHODS: The BIORISK ICAS (Biomarkers and Recurrence Risk in Symptomatic Intracranial Atherosclerosis) is a multicenter retrospective international study (35 sites) that included hospitalized patients with symptomatic ICAS (50%–99% luminal stenosis of the intracranial vertebral, basilar, distal internal carotid, or proximal middle cerebral artery) from January 2019 to June 2024. The primary outcome was recurrent ischemic stroke in the territory of the symptomatic artery within 90 days. In the primary analysis, the exposure was an acute anterior circulation borderzone infarct. In secondary analysis of the subset with presentation within 72 hours of last known normal and perfusion imaging completed, the exposure of interest was prespecified as hypoperfusion mismatch volume at T max (time to maximum) threshold of 6 seconds, dichotomized at the Youden index. We performed multivariable Cox regression to test associations between exposure variables and the outcome, adjusting for clinically relevant variables and those associated with the outcome ( P <0.1). RESULTS: Of 2050 patients with symptomatic ICAS, 1737 (84.7%) presented within 72 hours of symptom onset, among whom 509 (29.3%) underwent perfusion imaging. The primary analysis included 1891 patients; 174 (9.2%) patients had recurrent ischemic stroke in the symptomatic arterial territory. In adjusted Cox regression models, there was an association between anterior circulation borderzone infarct and recurrent ischemic stroke at 90 days (adjusted hazard ratio, 1.40 [95% CI, 1.02–1.93]). In the perfusion imaging analysis, hypoperfusion mismatch of ≥10 mL was associated with recurrent ischemic stroke (adjusted hazard ratio, 1.83 [95% CI, 1.03–3.28]). CONCLUSIONS: Biomarkers of impaired distal perfusion, anterior circulation borderzone infarct, and hypoperfusion mismatch were associated with increased risk of recurrent ischemic stroke. These findings support the use of perfusion imaging in ICAS as well as future trials investigating early reperfusion in high-risk patients with ICAS.
3D‐Printed Microfluidic Platform for Creating Porous Nanofibrous Microspheres to Regulate Cell Response and Enhance Tissue Regeneration (Small 41/2025)
Sharma, Navatha Shree , Killeen, Amy C., Reinhardt, Richard A., Lee, Dong-Hee , Tran, Huy Quang , Andrabi, Syed Muntazir , Yan, Zishuo , Zhu, Wuqiang , Xie, Jingwei

Mayo Clinic

Small | October 16, 2025 | Volume: 21 | Issue: 41 | Pages: No page available

10.1002/smll.70735 Get It

Targeted Therapy Improves Real-World Survival in Patients with Molecularly Matched Advanced Biliary Tract Cancer
Bekaii‐Saab, Tanios , Zheng-Lin, Binbin , Eslinger, Cody , Ramaker, Ryne C. , Itoh, Shinji , Hashimoto, Tadayoshi , Imai, Mitsuho , Pirozzi, Angelo , Hoyek, Celine , Moyer, Ashley , Ueno, Makoto , Morizane, Chigusa, Ahn, Daniel H. , Gottam, Madhuri, Bekaii-Saab, Tanios S , Shibuki, Taro , Kosiorek, Heidi , Abidoye, Oluseyi , Kawamoto, Yasuyuki , Fujisawa, Takao , Sonbol, Mohamad Bassam , Wu, Christina , Tran, Nguyen, Babiker, Hani M. , Roberts, Lewis R. , Nakamura, Yoshiaki , Bando, Hideaki , Yoshino, Takayuki , Morizane, Chigusa , Borad, Mitesh J. , Strickler, John H. , Ikeda, Masafumi

Mayo Clinic

No container title available | October 12, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-7744614/v1 Get It

Abstract Molecular profiling reveals that up to 40% of advanced biliary tract cancers (BTCs) harbor actionable genomic alterations amenable to matched targeted therapies. However, conventional trial designs typically evaluate these agents in pretreated populations, resulting in approvals for later-line use. Notably, 25–44% of patients with advanced BTC may become ineligible for treatment after first-line therapy due to disease progression or functional decline, thus the real-world survival outcomes with matched therapies remains poorly characterized. This international collaborative study includes data from Mayo Clinic, Duke Cancer Institute, and National Cancer Center East (Japan), as well as a combined dataset from the SCRUM-Japan GOZILA, MONSTAR-SCREEN-1, and MONSTAR-SCREEN-2 projects. We assessed overall survival (OS) of patients based on the presence of actionable alterations and the receipt of matched therapy. To adjust for confounding, we applied propensity score weighting with inverse probability of treatment and multivariate Cox regression modeling, controlling for age, sex, tumor location, prior resection, and mutational subgroup. Among 1,049 patients that were analyzed, 358 (34.1%) harbored actionable alterations, with 160 (44.7%) receiving matched targeted therapy. The matched group (patients with actionable tumors who received a matched therapy) were significantly associated with longer median OS (23.3 months; 95% CI: 19.5–30.4) compared to the unmatched group (14.7 months; 95% CI: 12.8–17.9) and those with non-actionable tumors (17.1 months; 95% CI: 15.5–18.7; HR 0.57, 95% CI: 0.46–0.71; p < 0.0001). The unmatched group also was associated with the lowest three-year OS rate (13% vs. 35% in matched and 19% in actionable groups, respectively; p<0.0001). On multivariable analysis with patients who received ≥2 lines of therapy, receipt of matched therapy remained an independent predictor of improved OS (HR 0.62; 95% CI 0.43–0.90). These findings support the early integration of targeted therapies in BTC management and underscore the need to overcome systemic barriers to treatment access.
Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancer
Hibshman, Priya S. , Stalnecker, Clint A. , Drizyte‐Miller, Kristina , Klomp, Jennifer E. , Edwards, A. Cole , Pita, Lily M. , Hodge, Richard G. , Diehl, J. Nathaniel , Mouery, Ryan D. , Mouery, Brandon L. , Snare, Kayla R., Waters, Andrew M. , Peng, Sen, Barker, Natalie K. , Pierobon, Mariaelena , Rashid, Naim U. , Tran, Nhan L. , Herring, Laura E. , Graves, Lee M. , Petricoin, Emanuel F. , Bryant, Kirsten L. , Cox, Adrienne D. , Klomp, Jeffrey A , Drizyte-Miller, Kristina , Klomp, Jennifer E , Edwards, A Cole , Hodge, Richard G , Diehl, J Nathaniel , Mouery, Brandon L , Snare, Kayla R , Waters, Andrew M , Barker, Natalie K , Herring, Laura E , Graves, Lee M , Petricoin, Emanuel F , Bryant, Kirsten L , Cox, Adrienne D , Der, Channing J , Stalnecker, Clint A , Tran, Nhan L

Mayo Clinic

Science Signaling | September 30, 2025 | Volume: 18 | Issue: 906 | Pages: No page available

10.1126/scisignal.adu7145 | PMID 41026826 Get It

Of the thousands of genes and substrates identified in KRAS-mutant signaling networks in pancreatic ductal adenocarcinoma (PDAC), more than 200 are transcription factors, implying extensive and complex transcriptional regulation. However, we observed that genetic suppression of the transcription factor MYC alone was sufficient to phenocopy the effect of KRAS suppression in signaling, growth, and metabolic processes in PDAC cells. We determined the gene transcription changes caused by acute suppression of MYC function in KRAS -mutant PDAC cell lines and performed dependency map and pathway analyses on the affected gene sets. The expression of 1685 genes was increased upon suppression of MYC, and this gene set may comprise the bulk of the MYC-regulated genes essential for PDAC growth. In contrast, the 1325 genes whose expression was inhibited may comprise a compensatory response to oncogenic stress, mediated in part by the GTPase RHO. MYC-dependent transcriptional activity was largely ERK dependent, and almost one-third of ERK-regulated genes were also regulated by MYC in PDAC cells. Furthermore, chemical proteomic profiling revealed MYC-regulated protein kinases that can be targeted therapeutically. Together, these data provide a molecular portrait of MYC-dependent signaling that encompasses potentially exploitable mechanisms for treating PDAC.
Post‐Marketing Safety of Bimekizumab in Psoriasis Patients: Pharmacovigilance Data From FDA Adverse Event Reporting System
Tran, Tung S, Le, Duc V. , Jacobs, Jena C., Nguyen, Trang M , Wetter, David A., Nguyen, Giang Huong , Tran, Tung S. , Le, Duc V. , Tran, Tung S , Le, Duc V. , Nguyen, Giang H , Nguyen, Trang M , Le, Duc V., Jacobs, Jena C., Wetter, David A.

Mayo Clinic

International Journal of Dermatology | September 24, 2025 | Volume: 65 | Issue: 4 | Pages: 825-827

10.1111/ijd.70082 | PMID 40990361 Get It

First-line atezolizumab/bevacizumab or durvalumab/tremelimumab in advanced hepatocellular carcinoma: a real world, multicenter retrospective study
Kournoutas, Ioannis , Marell, Paulina S. , Peersen, Anina, Shah, Priyanshi , VanDommelen, Kyle, Gupta, Garima , Akce, Mehmet , Yang, Ju Dong , Chen, Pin‐Jung , Naleid, Nikolas , Peterson, Nicole , Sahai, Vaibhav , Halfdanarson, Thorvardur, Kankeu, Lionel Fonkoua, Washburn, Leslie, Conboy, Caitlin B. , Goenka, Ajit H. , Thompson, Scott A. , Ahn, Daniel H. , Jatoi, Aminah , Marell, Paulina, Gile, Jennifer , Yang, Ju Dong , Sahai, Vaibhav , Jin, Zhaohui , Fonkoua, Lionel Aurelien A Kankeu , Washburn, Leslie A, Goenka, Ajit, Starlinger, Patrick , Roberts, Lewis, Jatoi, Aminah , Ou, Fang-Shu , Tran, Nguyen , Conboy, Caitlin B , Kamath, Suneel Deepak , Mahipal, Amit , Wee, Wen , Jin, Zhaohui , Fonkoua, Lionel Aurelien Kankeu , Torbenson, Michael , Thompson, Scott, Venkatesh, Sudhakar K. , Starlinger, Patrick , Roberts, Lewis R. , Gores, Gregory J. , Babiker, Hani M. , Borad, Mitesh J. , Bekaii‐Saab, Tanios , McWilliams, Robert R. , Ou, Fang‐Shu

Mayo Clinic

The Oncologist | September 20, 2025 | Volume: 30 | Issue: 11 | Pages: No page available

10.1093/oncolo/oyaf286 | PMID 40973475 Get It

Abstract Background Unresectable hepatocellular carcinoma (uHCC) is a leading cause of cancer death. FDA-approved first-line systemic therapies include atezolizumab/bevacizumab (atezo/bev) and durvalumab/tremelimumab (durva/treme); however, there is a lack of comparative data. Methods We reviewed outcomes of patients with uHCC who initiated atezo/bev or durva/treme between 2017 and 2024, across six institutions. Overall survival (OS) and time to treatment discontinuation (TTD) were analyzed using the Kaplan–Meier and Cox models, adjusting for baseline characteristics. Results Four hundred fifty-two uHCC pts were included. Median age: 68 years; 77% male; 81% white. Most common etiologies were viral hepatitis (38.9%) and metabolic dysfunction-associated steatohepatitis (19.5%). Disease progression was the primary reason for treatment discontinuation, atezo/bev (56%) and durva/treme (42%). Outcomes were not statistically significant (median OS [month, m]: 14.0 vs 14.6 [P = .66]; median TTD [m]: 4.9 vs 3.9 [P = .42] for atezo/bev vs durva/treme). Outcomes were significantly different between Child-Pugh classes (CP: A, B7, B8/9, C) respectively, median OS(m): 19.0, 6.1, 5.1, 2.0 (P &lt; .001); median TTD(m): 6.1, 2.3, 3.0, 1.3 (P &lt; .001). Conclusions In this real-world study of uHCC, no significant difference in clinical outcomes was observed between atezo/bev and durva/treme in the first-line setting. CP scores were a key prognostic variable with both regimens.
Circulating Tumor DNA and Tissue Testing for Pancreatobiliary Tumors
Majeed, Umair , Patel, Jaydeepbhai, Ahmed, Ahmed , Elhariri, Ahmed , Albelal, Douaa , Rao, Nakka Naga Malleswara, Rachamala, Hari Krishnareddy, Mahadevan, Daruka , Ahn, Daniel H. , Halfdanarson, Thor R, Fonkoua, Lionel Aurelien Kankeu , Bekaii-Saab, Tanios S , Mody, Kabir , Babiker, Hani, Nakka, Naga Malleswara Rao , Ahmed, Ahmed K , Mosalem, Osama , Sonbol, Mohamad Bassam , Tran, Nguyen , Kankeu Fonkoua, Lionel A, Majeed, Umair , Mahadevia, Himil , Rao, Nakka Naga Malleswara, Rachamala, Hari Krishnareddy, Mukhopadhyay, Debabrata , Jones, Jeremy C , Borad, Mitesh J. , Tran, Nguyen, Mahipal, Amit , Wee, Wen , McWilliams, Robert R. , Bekaii‐Saab, Tanios

Mayo Clinic

JAMA Network Open | September 12, 2025 | Volume: 8 | Issue: 9 | Pages: e2531373

10.1001/jamanetworkopen.2025.31373 | PMID 40938601 Get It

Importance The prognosis of advanced pancreaticobiliary tumors is poor. Next-generation sequencing (NGS) of tissue samples is utilized to identify actionable alterations, but there are occasional limitations due to inadequate tissue acquisition. Circulating tumor DNA (ctDNA) is an alternative method, but its correlation with tissue-based NGS remains unexplored. Objectives To assess the mutation concordance (mCR) rates between ctDNA and tissue testing for patients with pancreatic ductal adenocarcinoma (PDAC) and cholangiocarcinoma (CC) and to evaluate how ctDNA performs as a treatment response biomarker. Design, Setting, and Participants This retrospective cohort study was conducted among patients with PDAC and CC treated at academic institutions from January 2014 to January 2025. Patients underwent ctDNA testing using 1 platform and tissue NGS testing using 2 platforms. Main Outcomes and Measures mCR, which measures the shared gene alterations observed by both ctDNA and tissue-based NGS testing, was calculated using the Spearman correlation for PDAC and CC. The performance of ctDNA as a treatment response biomarker was assessed by comparing serial ctDNA data with restaging scans and cancer antigen 19-9 levels in patients with PDAC. Results Our cohort included 790 patients: 570 with advanced PDAC (265 [46.5%] female; median [IQR] age, 64 [33-84] years) and 220 with advanced CC (95 [43.2%] female; median [IQR] age, 66 [42-88] years). Overall, 461 patients with PDAC (80.9%) and 192 patients with CC (87.2%) underwent ctDNA testing, while 239 patients with PDAC (41.9%) and 70 patients with CC (31.8%) had tissue NGS testing. Among patients with PDAC, 85 of 130 patients (65.4%) showed shared specific gene alterations between ctDNA and tissue testing; there was a significant mCR, with a Spearman correlation of 0.47 (95% CI, 0.28-0.62; P &amp;lt; .001). For patients with CC, 32 of 48 (66.7%) had shared alterations between ctDNA and tissue testing; there was a significant mCR, with a Spearman correlation of 0.56 (95% CI, 0.35-0.70; P &amp;lt; .001). A subgroup analysis of patients with PDAC who underwent serial ctDNA testing suggested that new TP53 subclones and increased ctDNA variant allele frequency levels of TP53 and KRAS were associated with higher odds of progressive disease (eg, increased TP53 frequency: odds ratio, 7.28; 95% CI, 2.15-24.66; P = .001). Conclusions and Relevance In this cohort study of patients with pancreaticobiliary tumors, there was a significant mCR between ctDNA and tissue NGS testing. Additionally, results suggest that ctDNA might detect resistant clones and enable assessment of treatment response.